p16INK4A-silencing augments DNA damage-induced apoptosis in cervical cancer cells

Oncogene

Volumn 26, Issue 41, 2007, Pages 6050-6060

  Lau, W M ^a   Ho, T H ^b,c   Hui, K M ^a  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

^c KK WOMEN'S AND CHILDREN'S HOSPITAL   (Singapore)

Author keywords

Apoptosis; Cervical cancer; DNA damage; p16; RNAi

Indexed keywords

CISPLATIN; PROTEIN E7; PROTEIN P14ARF; PROTEIN P16INK4A; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN; SMALL INTERFERING RNA; COMPLEMENTARY DNA;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER TISSUE; CARCINOGENESIS; CELL CYCLE PROGRESSION; CONTROLLED STUDY; DNA DAMAGE; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE LOCUS; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SQUAMOUS CELL CARCINOMA; ULTRAVIOLET IRRADIATION; UPREGULATION; UTERINE CERVIX CARCINOMA; CELL CULTURE; CYTOLOGY; DNA MICROARRAY; GENETICS; PATHOLOGY; TUMOR SUPPRESSOR GENE; UTERINE CERVIX; UTERINE CERVIX TUMOR;

APOPTOSIS; CELLS, CULTURED; CERVIX UTERI; DNA DAMAGE; DNA, COMPLEMENTARY; FEMALE; GENE SILENCING; GENES, P16; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RNA, SMALL INTERFERING; TRANSFECTION; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS;

EID: 34548496015     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210405     Document Type: Article

References (43)

1. Andersson S, Hansson B, Norman I, Gaberi V, Mints M, Hjerpe A et al. (2006). Expression of E6/E7 mRNA from 'high risk' human papillomavirus in relation to CIN grade, viral load and p16INK4a. Int J Oncol 29: 705-711.
2. Bode AM, Dong Z. (2004). Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 4: 793-805.
3. Butz K, Shahabeddin L, Geisen C, Spitkovsky D, Ullmann A, Hoppe-Seyler F. (1995). Functional p53 protein in human papillomavirus-positive cancer cells. Oncogene 10: 927-936.
4. Cheng Q, Lau WM, Tay SK, Chew SH, Ho TH, Hui KM. (2002). Identification and characterization of genes involved in the carcinogenesis of human squamous cell cervical carcinoma. Int J Cancer 98: 419-426.
5. Demers GW, Foster SA, Halbert CL, Galloway DA. (1994). Growth arrest by induction of p53 in DNA damaged keratinocytes is bypassed by human papillomavirus 16 E7. Proc Natl Acad Sci USA 91: 4382-4386.
6. el-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J et al. (1994). WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54: 1169-1174.
7. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM et al. (1993). WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825.
8. Freedman DA, Levine AJ. (1998). Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol Cell Biol 18: 7288-7293.
9. Giarre M, Caldeira S, Malanchi I, Ciccolini F, Leao MJ, Tommasino M. (2001). Induction of pRb degradation by the human papillomavirus type 16 E7 protein is essential to efficiently overcome p16INK4a-imposed G1 cell cycle Arrest. J Virol 75: 4705-4712.
10. Goodwin EC, DiMaio D. (2000). Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways. Proc Natl Acad Sci USA 97: 12513-12518.
11. Goodwin EC, Yang E, Lee CJ, Lee HW, DiMaio D, Hwang ES. (2000). Rapid induction of senescence in human cervical carcinoma cells. Proc Natl Acad Sci USA 97: 10978-10983.
12. Gu W, Putral L, Hengst K, Minto K, Saunders NA, Leggatt G et al. (2006). Inhibition of cervical cancer cell growth in vitro and in vivo with lentiviral-vector delivered short hairpin RNA targeting human papillomavirus E6 and E7 oncogenes. Cancer Gene Ther 13: 1023-1032.
13. Haapajarvi T, Kivinen L, Heiskanen A, des Bordes C, Datto MB, Wang XF et al. (1999). UV radiation is a transcriptional inducer of p21(Cip1/Waf1) cyclin-kinase inhibitor in a p53-independent manner. Exp Cell Res 248: 272-279.
14. Hawley-Nelson P, Vousden KH, Hubbert NL, Lowy DR, Schiller JT. (1989). HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J 8: 3905-3910.
15. Ishikawa M, Fujii T, Saito M, Nindl I, Ono A, Kubushiro K et al. (2006). Overexpression of p16 INK4a as an indicator for human papillomavirus oncogenic activity in cervical squamous neoplasia. Int J Gynecol Cancer 16: 347-353.
16. Jiang M, Milner J. (2002). Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference. Oncogene 21: 6041-6048.
17. Jimenez GS, Khan SH, Stommel JM, Wahl GM. (1999). p53 regulation by post-translational modification and nuclear retention in response to diverse stresses. Oncogene 18: 7656-7665.
18. Jones DL, Munger K. (1997). Analysis of the p53-mediated G1 growth arrest pathway in cells expressing the human papillomavirus type 16 E7 oncoprotein. J Virol 71: 2905-2912.
19. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV et al. (1994). A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436-440.
20. Kanao H, Enomoto T, Ueda Y, Fujita M, Nakashima R, Ueno Y et al. (2004). Correlation between p14(ARF)/p16(INK4A) expression and HPV infection in uterine cervical cancer. Cancer Lett 213: 31-37.
21. Klaes R, Friedrich T, Spitkovsky D, Ridder R, Rudy W, Petry U et al. (2001). Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 92: 276-284.
22. Lee YS, Wan J, Kim BJ, Bae MA, Song BJ. (2006). Ubiquitin-dependent degradation of p53 protein despite phosphorylation at its N terminus by acetaminophen. J Pharmacol Exp Ther 317: 202-208.
23. Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P et al. (2003). p53 has a direct apoptogenic role at the mitochondria. Mol Cell 11: 577-590.
24. Muller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, Li-Weber M et al. (1998). p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 188: 2033-2045.
25. Munger K, Scheffner M, Huibregtse JM, Howley PM. (1992). Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products. Cancer Surv 12: 197-217.
26. Nevins JR. (1992). E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science 258: 424-429.
27. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. (1994). Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368: 753-756.
28. Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T et al. (2000). p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 102: 849-862.
29. Parkin DM, Bray FI, Devesa SS. (2001). Cancer burden in the year 2000. The global picture. Eur J Cancer 37: S4-S66.
30. Putral LN, Bywater MJ, Gu W, Saunders NA, Gabrielli BG, Leggatt GR et al. (2005). RNA interference against human papillomavirus oncogenes in cervical cancer cells results in increased sensitivity to cisplatin. Mol Pharmacol 68: 1311-1319.
31. Queiroz C, Silva TC, Alves VA, Villa LL, Costa MC, Travassos AG et al. (2006). P16(INK4a) expression as a potential prognostic marker in cervical pre-neoplastic and neoplastic lesions. Pathol Res Pract 202: 77-83.
32. Sano T, Oyama T, Kashiwabara K, Fukuda T, Nakajima T. (1998). Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol 153: 1741-1748.
33. Scheffner M, Munger K, Byrne JC, Howley PM. (1991). The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc Natl Acad Sci USA 88: 5523-5527.
34. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. (1990). The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129-1136.
35. Shapiro GI, Edwards CD, Ewen ME, Rollins BJ. (1998). p16INK4A participates in a G1 arrest checkpoint in response to DNA damage. Mol Cell Biol 18: 378-387.
36. Shieh SY, Ikeda M, Taya Y, Prives C. (1997). DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91: 325-334.
37. Slebos RJ, Lee MH, Plunkett BS, Kessis TD, Williams BO, Jacks T et al. (1994). p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein. Proc Natl Acad Sci USA 91: 5320-5324.
38. Smotkin D, Wettstein FO. (1986). Transcription of human papillomavirus type 16 early genes in a cervical cancer and a cancer-derived cell line and identification of the E7 protein. Proc Natl Acad Sci USA 83: 4680-4684.
39. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV et al. (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189: 12-19.
40. Yamamoto A, Kumakura S, Uchida M, Barrett JC, Tsutsui T. (2003). Immortalization of normal human embryonic fibroblasts by introduction of either the human papillomavirus type 16 E6 or E7 gene alone. Int J Cancer 106: 301-309.
41. Zhang J, Pickering CR, Holst CR, Gauthier ML, Tlsty TD. (2006). p16INK4a modulates p53 in primary human mammary epithelial cells. Cancer Res 66: 10325-10331.
42. zur Hausen H. (1996). Papillomavirus infections - a major cause of human cancers. Biochim Biophys Acta 1288: F55-78.
43. zur Hausen H. (2002). Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2: 342-350.